In fact, cancer cells up-regulate the expression levels of PD-L1 in response to INF-γ released from infiltrating T cells and in this way acquire immune resistance [49], while becoming more likely responsive to therapy directed against the PD-1/PD-L1 axis. Here, CD274 is linked to cancer.